We are live on ! Find out more
BLRX

BioLineRX
BLRX

18 hedge funds and large institutions have $6.66M invested in BioLineRX in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

23% more capital invested

Capital invested by funds: $5.42M → $6.66M (+$1.24M)

13% more funds holding

Funds holding: 16 → 18 (+2)

0.01% more ownership

Funds ownership: 0.03% → 0.03% (+0.01%)

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
+$1.31M
2
Morgan Stanley
Morgan Stanley
New York
+$384K
3
Renaissance Technologies
Renaissance Technologies
New York
+$208K
4
TNB
Thomasville National Bank
Georgia
+$23.7K
5
CCB
Cutter & Co Brokerage
Missouri
+$21.2K

Top Sellers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
-$227K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$32K
3
Goldman Sachs
Goldman Sachs
New York
-$26.4K
4
LPL Financial
LPL Financial
California
-$5.67K
5
ADL
Asset Dedication LLC
California
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$2.77M – – –
Morgan Stanley
2
Morgan Stanley
New York
$1.26M +$384K +5,080 +36%
KCM
3
Kennedy Capital Management
Missouri
$1.14M +$1.31M +17,389 New
SM
4
Senvest Management
New York
$543K -$227K -3,000 -27%
Renaissance Technologies
5
Renaissance Technologies
New York
$438K +$208K +2,748 +70%
PVH
6
Psagot Value Holdings
Israel
$192K – – –
O
7
OrbiMed
New York
$114K – – –
CCB
8
Cutter & Co Brokerage
Missouri
$48K +$21.2K +280 +63%
Goldman Sachs
9
Goldman Sachs
New York
$39K -$26.4K -349 -37%
OM
10
Opaleye Management
Massachusetts
$33K – – –
LPL Financial
11
LPL Financial
California
$28K -$5.67K -75 -15%
Creative Planning
12
Creative Planning
Kansas
$22K +$3.78K +50 +17%
TNB
13
Thomasville National Bank
Georgia
$21K +$23.7K +313 New
UBS Group
14
UBS Group
Switzerland
$7K +$7.86K +104 New
NFG
15
Next Financial Group
Texas
$6K +$6.8K +90 New
RE
16
RBC Europe
United Kingdom
$21 – – –
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
– -$32K -474 Closed
ADL
18
Asset Dedication LLC
California
– -$1K -9 Closed

BLRX Hedge Fund Activity: Q3 2020 in Review

18 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2020, worth a combined $6.66M — up 23% from $5.42M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BLRX positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $1.31M. The largest seller was Senvest Management, cutting an estimated $227K.

  • 18 institutional investors held BioLineRX (BLRX) as of Q3 2020, up from 16 in Q2 2020.
  • Funds reported $6.66M of BioLineRX stock for Q3 2020, up 23% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q3 2020 and 2 closed out, a net change of +2 holders.
  • The largest BioLineRX buyer in Q3 2020 was Kennedy Capital Management, an estimated $1.31M added.
  • The largest BioLineRX seller in Q3 2020 was Senvest Management, an estimated $227K sold.

Based on aggregated 13F filings for Q3 2020.